Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02256839 · ClinicalTrials.gov registry record
Evaluation of the QuantiFERON-TB Test.
A clinical trial of Tuberculosis, sponsored by QIAGEN Gaithersburg.
- Completed
- Registry status
- 268
- Enrollment target
- 1
- Study location
NCT02256839: Completed study of Tuberculosis, sponsored by QIAGEN Gaithersburg.
NCT02256839 is a study of Tuberculosis that has completed, run by QIAGEN Gaithersburg. The registered enrollment target is 268 participants, below the 925-participant average among 29 other Tuberculosis trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02256839, a study of Tuberculosis, has completed, sponsored by QIAGEN Gaithersburg.
- COMPLETED
- Registry status
- 268 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.
Primary Outcome
To compare the clinical specificity of the CST001 assay to the QuantiFERON-TB Gold test in low TB exposure risk subjects and non TB infected subjects based on an assessment of known risk factors. These subjects had no identified risk factors of TB infection.
Conditions Studied
Interventions
- DEVICE CST_001
Study Locations (1)
Oregon
- Oregon Health & Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-10 |
What the finished NCT02256839 record still lists
NCT02256839 is an observational study that tracks outcomes without assigning an intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 925-participant average among 29 other Tuberculosis trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 1 intervention - of which CST_001 is the first listed.
NCT02256839 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02256839 about?
NCT02256839 is a clinical study titled "Evaluation of the QuantiFERON-TB Test.". To compare the results of the investigational test to the currently approved QuantiFERON-TB Gold In-Tube test.
What is the current status of trial NCT02256839?
This trial is currently completed. The enrollment target is 268 participants. The study started on 2014-10. Estimated completion is 2015-10.
What conditions does trial NCT02256839 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT02256839?
The interventions under investigation include: CST_001 (DEVICE).
Who is sponsoring clinical trial NCT02256839?
This trial is sponsored by QIAGEN Gaithersburg, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02256839 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02256839's enrollment target sits among peer trials
268 5th of 29 higher than 25 of 29 other Tuberculosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tuberculosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
RECRUITING
-
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
ACTIVE NOT RECRUITING
-
Gene Expression in HIV and Tuberculosis Co-infection
COMPLETED
-
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
COMPLETED · Phase 1
-
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia